研究单位：[1]Shanghai Oriental Hospital[2]Lyvgen Biopharma Holdings Limited[3]Anhui Cancer Hospital,Hefei,Anhui,China,230000[4]Beijing Cancer Hospital,Beijing,China,100142[5]Beijing Tongren Hospital Affiliated to Capital Medical University,Beijing,China,100730[6]Fujian cancer hospital,Fuzhou,Fujian,China,350014[7]Sun Yat-sen Memorial Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510120[8]Guangxi Medical University Cancer Hospital,Nanning,Guangxi,China,530021[9]Henan cancer hospital,Zhengzhou,Henan,China,450008[10]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430000[11]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[12]Xiangya Hospital Central South University,Changsha,Hunan,China,410008[13]The Second Xiangya Hospital, Central South University,Changsha,Hunan,China,410011[14]Hunan Cancer Hospital,Changsha,Hunan,China,410031[15]Hunan Cancer Hospital,Changsha,Hunan,China,410031[16]Liaoning cancer hospital,Shenyang,Liaoning,China,110042[17]Shanghai Oriental Hospital,Shanghai,Shanghai,China,200123[18]West China Hospital of Sichuan University,Chengdu,Sichuan,China,610041[19]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022
研究目的：
The purpose of this study is to assess the safety and efficacy of LVGN6051 (4-1BB agonistic antibody) combined with toripalimab (anti-PD-1 antibody) and paclitaxel (anti-tubulin chemotherapy) in patients with recurrent/metastatic head and neck squamous cell carcinoma who rapidly progress from previous neoadjuvant, curative, or adjuvant platinum-containing therapy, or who are currently contraindicated for platinum-containing treatment.
